INT183759

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.28
Pain Relevance 0.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Csf2) extracellular region (Csf2)
Csf2 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 95 100.00 Very High Very High Very High
antagonist 34 99.16 Very High Very High Very High
aspirin 1 94.28 High High
Inflammation 96 71.40 Quite High
agonist 20 43.76 Quite Low
withdrawal 2 38.24 Quite Low
chemokine 23 5.00 Very Low Very Low Very Low
Inflammatory response 6 5.00 Very Low Very Low Very Low
methotrexate 4 5.00 Very Low Very Low Very Low
Inflammatory mediators 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 146 100.00 Very High Very High Very High
Asthma 315 96.88 Very High Very High Very High
Eosinophilia 19 92.00 High High
INFLAMMATION 103 71.40 Quite High
Opportunistic Infections 34 65.52 Quite High
Rhinitis 11 56.64 Quite High
Neutropenia 2 12.88 Low Low
Infection 49 5.00 Very Low Very Low Very Low
Disease 31 5.00 Very Low Very Low Very Low
Targeted Disruption 20 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the largest double blind, randomized controlled trial on GM-CSF use in HIV infected individuals published to date, 309 subjects stratified according to viral load (?
Negative_regulation (published) of Localization (use) of GM-CSF associated with acquired immune deficiency syndrome or hiv infection
1) Confidence 0.42 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1164429 Disease Relevance 0.39 Pain Relevance 0
Finally, a Swiss study evaluated the use of GM-CSF 300 ?
Negative_regulation (evaluated) of Localization (use) of GM-CSF
2) Confidence 0.42 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1164429 Disease Relevance 0.16 Pain Relevance 0
In vitro, the cysteinyl-leukotriene receptor antagonist pranlukast can concentration-dependently inhibit the release of Th2 cytokines (IL-3, IL-4, GM-CSF), but not of the Th1 cytokine IL-2, from mite allergen-stimulated PBMCs from asthmatic patients [37].
Negative_regulation (inhibit) of Localization (release) of GM-CSF associated with asthma, antagonist and cytokine
3) Confidence 0.05 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.73 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox